In order to reduce the prevalence of cigarette smoking among Veterans, it is vital that the investigators offer effective tobacco treatment to all Veterans who smoke, including those not ready to make a quit attempt. Smoking treatments currently available to Veterans who are not ready to quit are only weakly effective. This project will generate new knowledge about the effectiveness of a promising varenicline-based intervention designed to increase quit attempts and long-term abstinence in Veterans who are initially not ready to quit. This project has great potential to engage Veterans not ready to quit smoking in treatment that increases quit attempts and quitting success, thereby reducing morbidity and mortality caused by smoking in Veterans.

开始日期2025-12-01

申办/合作机构

VA Office of Research and Development

NCT07040566

/ Not yet recruiting临床2期IIT

Investigating Efficacious E-Cigarette Interventions and Cessation Effects on Cancer-Related Biomarkers: A Randomized Trial of Varenicline in Adults

This is randomized, placebo-controlled clinical trial in treatment-seeking adults who report regular e-cigarette use to test the hypothesis that varenicline is efficacious for quitting e-cigarettes.

开始日期2025-08-01

申办/合作机构

Yale University

[+1]

NCT06854406

/ Recruiting临床1期IIT

Varenicline in the Treatment of Visceral Sensation: A Pilot Study

The purpose of this study is to evaluate the effect of varenicline on rectal sensation, based on ascending method of limits and on graded rapid phasic distensions in participants with non-constipation IBS and chronic abdominal pain.

开始日期2025-06-01

申办/合作机构

Mayo Clinic

100 项与酒石酸伐尼克兰相关的临床结果

登录后查看更多信息

100 项与酒石酸伐尼克兰相关的转化医学

登录后查看更多信息

100 项与酒石酸伐尼克兰相关的专利（医药）

登录后查看更多信息

2,633

项与酒石酸伐尼克兰相关的文献（医药）

2025-09-01·DRUG AND ALCOHOL DEPENDENCE

A multi-site study examining the tobacco withdrawal trajectory in people with tobacco and cannabis co-use

Article

作者: Lerman, Caryn ; Schnoll, Robert ; George, Tony P ; Rabin, Rachel A ; Tyndale, Rachel F

BACKGROUND:

Approximately 30 % of people who use tobacco also use cannabis, and rates of co-use are rising. Relative to people who use tobacco alone (TO), individuals who co-use tobacco and cannabis (TC) experience greater difficulty with tobacco cessation, yet mechanisms underlying this phenomenon remain unexplored. Leveraging data from a multi-site, double-blind clinical trial for tobacco cessation, we compared the trajectory of tobacco withdrawal, a strong predictor of relapse, between TC and TO during 11-weeks of tobacco treatment.

METHODS:

People seeking treatment for tobacco were randomized to one of three arms (placebo, nicotine patch or varenicline) and followed for 11-weeks. Participants were parsed according to their cannabis use status determined by a cannabis-positive urine toxicology at screen (N = 1246). We selected participants with end-of-treatment biochemically verified 7-day point prevalence tobacco abstinence (N = 330; TC, n = 55 and TO, n = 275) and examined group differences in tobacco withdrawal severity using the Minnesota Nicotine Withdrawal Scale (MNWS) at baseline, week 1, 4, 8, and week 11 (end-of-treatment).

RESULTS:

Controlling for age, treatment arm, and site, we found a significant interaction (group x time) effect for withdrawal severity (p < 0.01). Bonferroni-corrected post-hoc comparisons revealed that relative to TO, TC had elevated withdrawal scores at week 1 (TC, M=9.3 ± 5.5; TO, M=7.1 ± 5.6; p < 0.01); no other timepoints showed between-group differences.

CONCLUSIONS:

People who co-use experience greater tobacco withdrawal severity one-week post abstinence compared to people who only use tobacco. Personalized interventions that target immediate tobacco withdrawal and/or cannabis use may help improve tobacco cessation rates for people who co-use both substances.

2025-09-01·DRUG AND ALCOHOL DEPENDENCE

Baseline predictors of smoking cessation among individuals with current or past major depressive disorder following treatment with varenicline and intensive behavioral treatment

Article

作者: Hitsman, Brian ; Papandonatos, George D ; D'Eletto, Michael ; Gollan, Jacqueline K ; Schnoll, Robert A

INTRODUCTION:

In a 2 × 2 factorial clinical trial with 300 individuals with current or past major depressive disorder (MDD), varenicline significantly increased smoking cessation, compared to placebo, whereas behavioral activation for smoking cessation yielded similar quit rates compared to standard behavioral treatment. In this secondary analysis, we evaluated whether participant characteristics at baseline predicted abstinence or moderated the effects of behavioral treatment or pharmacotherapy on abstinence.

METHODS:

The sample was racially and socioeconomically diverse and spanned varied psychiatric presentations: 49 % of participants had current MDD, 44 % had other mental health disorders, and only 27 % were being treated for their depression. Self-reported 7-day point prevalence abstinence at end-of-treatment (EOT; Week 14) and long-term follow-up (Week 27) was confirmed using breath carbon monoxide (≤6 parts per million).

RESULTS:

In a logistic regression model, greater likelihood of abstinence at EOT was associated with varenicline vs. placebo (OR=5.52, 95 % CI=2.62-11.60), lower cigarette dependence (OR=0.42, 95 % CI=0.19-0.90), and fast nicotine metabolism (OR=1.64, 95 % CI=1.06-2.54). In second logistic regression model, greater likelihood of Week 27 abstinence was associated with varenicline vs placebo (OR=3.06, 95 % CI=1.32-7.07) and fast nicotine metabolism (OR=2.06, 95 % CI=1.20-3.54). None of the baseline factors interacted with behavioral or pharmacological treatment to predict abstinence at either time point.

CONCLUSIONS:

Varenicline should be a primary treatment consideration for individuals with MDD. Stable psychiatric status is not required for favorable treatment outcome. Further effort is needed to identify behavioral interventions that can be added to varenicline to improve quit rates for individuals with MDD.

2025-08-01·Contemporary Clinical Trials

Evaluating smoking cessation interventions for people living with HIV in a factorial randomised clinical trial in South Africa using the Multiphase Optimization Strategy (MOST) framework: The Tlogela Trial protocol

Article

作者: Sohn, Hojoon ; Nabeemeeah, Firdaus ; Genade, Leisha P ; Mlambo, Lebohang ; Nonyane, Bareng A S ; Golub, Jonathan E ; Chetty, Deshan ; Steiner, Laura ; Waja, Ziyaad ; Elf, Jessica L ; Martinson, Neil ; Niaura, Raymond S ; Hoffmann, Christopher J ; Guastaferro, Kate ; Kemp, Christopher G

BACKGROUND:

Human immunodeficiency virus (HIV) remains an important cause of morbidity and mortality in South Africa (SA) with a gradual shift from opportunistic illness to pulmonary and cardiovascular disease among people living with HIV (PLWH). This shift is exacerbated by increases in prevalence of tobacco smoking and also few resources to support smoking cessation. Evidence-based smoking cessation strategies are yet to be fully evaluated among PLWH in this setting.

OBJECTIVE:

This project will optimize a smoking cessation treatment package for PLWH that can be integrated into existing HIV care in SA. We will identify the most effective and/or combination of the interventions and evaluate their potential for implementation and cost-effectiveness.

METHODS:

A balanced 2⁴ full factorial clinical trial will randomise 660 PLWH who smoke tobacco into one of 16 combinations of four intervention components (behavioural counselling, peer counselling, varenicline, and combination nicotine replacement therapy). Participants will be recruited from four healthcare facilities in SA, receive 12 weeks of intervention and the primary outcome will be 7-day point prevalence tobacco abstinence from smoking at one year, measuring both exhaled breath carbon monoxide (CO) and urinary cotinine. A mixed methods approach will be used to evaluate implementation using the Reach, Effectiveness, Adoptions, Implementation, Maintenance framework. Cost, cost-effectiveness, and budget impact of each intervention combination will be evaluated.

CONCLUSION:

Results will inform which intervention components, and in what combination, are most efficacious in supporting smoking abstinence among PLWH in SA and those that have the greatest potential for effectiveness when brought to scale.

CLINICAL TRIAL REGISTRATION NUMBER:

South African National Clinical Trials Registry.

TRIAL NO:

DOH-27-062023-9076.

CLINICALTRIALS:

gov ID: NCT05413122.

193

项与酒石酸伐尼克兰相关的新闻（医药）

2025-07-18

·PRNewswire

Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis

PITTSBURGH, July 18, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing. Viatris Chief R&D Officer Philippe Martin said, "Given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study. Thank you to the patients and investigators who contributed to the trial." The Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions. In June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions. The Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. About the MR-139 3001 Phase 3 Study The MR-139 3001 Phase 3 trial consisted of a randomized, placebo-controlled, double-masked prospective study, with a total of 477 patients who were randomized to receive either MR-139 or placebo, self-administered to the eyelids twice daily, treated and observed over 12 weeks. For more information on the MR-139 study design, refer to ClinicalTrials.gov (NCT06400511). About Viatris Viatris Inc. (Nasdaq: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale, currently supplying high-quality medicines to approximately 1 billion patients around the world annually and touching all of life's moments, from birth to the end of life, acute conditions to chronic diseases. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world's most enduring health challenges, access takes on deep meaning at Viatris. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on LinkedIn, Instagram, YouTube and X (formerly Twitter). Forward-Looking Statements This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may include statements that a randomized, double-masked, vehicle-controlled, Phase 3 study to evaluate the efficacy and safety of pimecrolimus 0.3% (MR-139) ophthalmic ointment in subjects with blepharitis, did not meet its primary endpoint of complete resolution of debris after six weeks of twice daily dosing; given that the study did not meet its objective for patients suffering from blepharitis, we are evaluating the appropriate next steps for the Phase 3 program, which may include revising the planned additional Phase 3 study; the Company is focused on delivering novel therapies like Tyrvaya® and RYZUMVI®, while progressing a differentiated pipeline that addresses unmet needs in anterior segment conditions; in June 2025, Viatris announced positive top-line results from its Phase 3 LYNX-2 trial of MR-142 in keratorefractive patients experiencing visual disturbances under mesopic, low-contrast conditions; and the Company also announced positive top-line results from its second pivotal Phase 3 VEGA-3 Trial of MR-141 in treating presbyopia. Because forward-looking statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the uncertainties inherent in research and development, including the outcomes of clinical trials; the ability to meet anticipated clinical endpoints; the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from clinical studies; actions and decisions of healthcare and pharmaceutical regulators; our ability to comply with applicable laws and regulations; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market; products in development and/or that receive regulatory approval may not achieve expected levels of market acceptance, efficacy or safety; longer review, response and approval times as a result of evolving regulatory priorities and reductions in personnel at health agencies; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings on Viatris; Viatris' failure to achieve expected or targeted future financial and operating performance and results; goodwill or impairment charges or other losses; any changes in or difficulties with the Company's manufacturing facilities; risks associated with international operations; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties regarding future demand, pricing and reimbursement for the Company's products; uncertainties and matters beyond the control of management, including but not limited to general political and economic conditions, potential adverse impacts from future tariffs and trade restrictions, inflation rates and global exchange rates; and the other risks described in Viatris' filings with the Securities and Exchange Commission ("SEC"). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this press release other than as required by law. SOURCE Viatris Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果

2025-07-17

·远大医药官微

远大医药治疗干眼症的全球首创鼻喷产品OC-01正式获批后在中国大陆实现首批商业化处方落地

OC-01于2021年10月在美国获批上市，是目前全球首款且唯一一款获批增加干眼症患者泪液分泌的无防腐剂、多剂量、无菌包装鼻喷雾剂[1]；OC-01是高选择性的烟碱乙酰胆碱受体激动剂，可通过启动三叉神经副交感神经通路，增加基础泪液的分泌，从而有望实现增加干眼症患者的泪液分泌；OC-01一天仅需两次鼻喷给药，可避免传统滴眼药使用的繁琐性，有望提高患者的依从性，有望为干眼症患者提供一种耐受性良好且疗效确切的全新治疗选择。近日，远大医药(0512.HK)全球首创用于增加干眼症患者泪液分泌的鼻喷产品酒石酸伐尼克兰鼻喷雾剂(OC-01)，在正式获批后于中山大学附属第一医院和深圳市眼科医院实现中国大陆首批商业化处方落地。这一里程碑进展标志着中国干眼症治疗迎来全新选择：中国目前唯一一款获批上市的用于增加干眼症患者泪液分泌的鼻喷产品正式投入临床应用[1]，为中国干眼症患者提供一种全新的治疗方案。OC-01创新经鼻给药或提供干眼症全新治疗选择关于OC-01OC-01是高选择性的烟碱乙酰胆碱受体激动剂，普遍认为可通过启动三叉神经副交感神经通路，增加基础泪液的分泌，从而增加干眼症患者的泪液分泌。该产品于2021年10月在美国获批上市，是目前全球首款且唯一一款获批治疗患者干眼症症状的鼻喷雾剂[1]；中国大陆方面，该产品于2024年11月获得国家药监局批准上市；此外，OC-01于2023年2月在中国澳门特别行政区获批上市；于2023年4月作为进口临床急需药品，落地海南乐城医疗先行区；于2024年11月在中国台湾地区获批上市。关于干眼症及其治疗干眼症为临床常见的慢性眼表疾病，中国干眼症发病率大约在21%-30%，干眼症患者人群保守估计约3.6亿人。目前，医疗机构门诊就诊的干眼症患者占眼科总就诊人数的30%以上，预计未来5-10年，该比例可能会上升到40%，干眼症已成为影响国民健康的重要社会公共卫生问题。最常用的治疗方案为人工泪液，但天然泪液成分较为复杂，含有上千种成分，而目前已上市的人工泪液产品仅可仿真泪膜的单一或部分成分，难以真正做到天然泪液的替代；此外，市面上常见的人工泪眼产品多为眼表滴注的给药方式，需要频繁给药，存在长期药物刺激风险，影响患者依从性。因此，人工泪液的治疗效果存在较大的个体差异。 OC-01采用创新的经鼻给药方式，显著改善了干眼症患者的天然泪液分泌量，提高泪膜稳定性，阻断干眼病理生理的恶性循环。同时，OC-01一天仅需两次鼻喷给药，使用方便，可避免传统滴眼药使用的繁琐性，有望提高患者的依从性。该产品有望为干眼症患者提供一种耐受性良好且疗效确切的全新治疗选择。[2]推进全球创新产品研发夯实眼科领域行业地位远大医药始终以眼科领域作为重要战略发展方向之一，持续聚焦眼科药物创新，坚持专业化发展道路，不断提升行业地位和市场竞争力。目前，公司已构建“专业化、全系列、多品种”的创新药物产品体系，储备了治疗“近视”、“干眼症”、“翼状胬肉”、“眼科术后抗炎镇痛”、“蠕形螨睑缘炎”和“蠕形螨导致的睑板腺功能障碍”的多款全球创新产品，且取得了重大研发进展，未来三年将有多款创新产品有望获批上市。[3]其中，用于治疗蠕形螨睑缘炎的全球创新眼科药物GPN01768 (TP-03，洛替拉纳滴眼液，0.25%)已于2024年12月向药监局递交了新药上市申请并获得了受理，于2025年5月获得中国澳门特别行政区政府药物监督管理局批准上市；用于抗炎镇痛的激素纳米混悬滴眼液GPN00833于2024年11月完成国内III期临床研究并达到了临床终点；用于治疗翼状胬肉的创新改良型新药GPN00153 (CBT-001)于2024年3月完成中国III期临床研究首例患者入组，于2025年6月完成国际多中心III期临床研究全球中心全部患者入组；用于推迟儿童近视进展的全球创新眼科药物GPN00884于2024年6月完成中国I期临床研究首例患者入组给药。[3] 未来，公司将加快推进研发管线的全面化、差异化布局，不断丰富眼科细分领域的创新产品储备。此外，公司在眼科领域已吸引和培养了一批兼具临床经验和营销经验的专业人士，建立了以客户为中心，学术为主导的专业化营销团队，并与大型医药流通企业和连锁药店建立了长期稳定合作，形成了覆盖全国的营销网络。随着眼科创新产品的持续获批，公司将充分发挥该领域的核心优势，持续深耕眼科前沿创新赛道，进一步加强核心产品的专业化推广和品牌建设，为持续健康发展提供新动能。远大医药集团有限公司董事会表示：“本集团一直高度重视创新产品和先进技术的研发，未来将持续加大对全球创新产品和先进技术的投入，丰富和完善产品管线及产业布局，坚持‘全球化运营布局，双循环经营发展’策略，充分发挥本集团的产业优势和研发实力，快速将科技创新产品落地上市，为全球患者提供更先进更多样的治疗方案。”[1]根据现有公开信息；[2]根据产品III期临床试验数据，具体疗效因人而异；[3]研发风险提示：文中提及的在研产品尚未获得上市批准，其安全性和有效性需经完整临床研究及监管审批确认，不构成任何治疗承诺或商业推广。 ▲远大医药全球创新放射性产品SIR-Spheres®钇[90Y]微球注射液提前正式获得FDA批准新增适应症▲国际最高标准！远大医药全球首个全产业链智能化核药研发生产基地即将全面投入运营▲重磅！远大医药易甘泰®钇[90Y]微球注射液多项研究成果亮相国际舞台，彰显中国科研实力↑↓ 上下滑动了解更多➤关于远大医药远大医药（0512.HK）是一家科技创新型国际化医药企业，核心业务横跨制药科技、核药抗肿瘤诊疗及心脑血管精准介入诊疗科技、生物科技三大领域。集团以医药及生物工业为基础，以患者需求为核心，以科技创新为源动力，针对尚未满足的临床需求，加大对全球创新产品和先进技术的投入，丰富和完善产品管线，巩固和强化产业链布局，充分发挥本集团的产业优势和研发实力，为全球患者提供更先进更多样的治疗方案。经过近年的不懈努力，本集团发展基础更加稳健，经营规模更加巩固，业务结构逐步优化，经营方式持续提升，转型升级步伐加快，创新布局多点开花。本集团盈利能力持续增强，助力研发创新；良好的并购与整合能力，继续巩固发展规模；原料制剂一体化，完善产业链结构；业务与实体多元化，有效加强综合优势。“稳增长、强创新、谋布局”，本集团将继续秉承“综合优势、创新引领和全球拓展”的发展理念，采用“自主研发和全球拓展双轮驱动，全球化运营布局和双循环经营发展”策略，形成国内国外双循环联动发展并相互促进的新格局，致力于成为一家受医生和患者尊重并还原于社会的科技创新型国际化医药企业。 ➤前瞻性声明本新闻稿旨在分享本集团业务相关动态及进展，仅供医疗卫生专业人士参阅，非广告用途。本新闻稿信息仅供参考，不作为诊疗依据，如有身体不适请及时就医，本集团不对任何药品和/或适应症作推荐。本新闻稿中可能会包含某些前瞻性表述。这些表述本质上具有相当风险和不确定性。在使用"预期"、"相信"、"预测"、"期望"、"打算"及其他类似词语进行表述时，凡与本集团有关的，均属于前瞻性表述。本集团并无义务不断地更新这些预测性陈述。这些前瞻性表述是基于本集团管理层在做出表述时对未来事务的现有看法、假设、期望、估计、预测和理解。这些表述并非对未来发展的保证，会受到风险、不确性及其他因素的影响，有些是超出本集团的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本集团、本集团董事及雇员代理概不承担(1)更正或更新本网站所载前瞻性表述的任何义务；及(2)若因任何前瞻性表述不能实现或变成不正确而引致的任何责任。

2025-07-08

·FiercePharma

Achieve sparks up Omnicom pact, securing agency support for nicotine dependence drug launch

Omnicom is pulling in talent from several of its agencies to support the launch of Achieve's nicotine dependence treatment. Achieve Life Sciences has signed up Omnicom to support the launch of nicotine dependence treatment cytisinicline, positioning the biotech to tap into capabilities at multiple agencies to reach patients and healthcare professionals.Having generated smoking cessation data in phase 3 trials, Achieve has filed for FDA approval and begun to prepare to launch cytisinicline in the U.S. If approved, cytisinicline will be Achieve’s first commercial product and will become the first new smoking cessation drug on the market since Pfizer launched Chantix in 2006. Jaime Xinos, chief commercial officer at Achieve, discussed how those factors are shaping the launch strategy, saying in a statement, “As an emerging biopharma company, we recognize we can’t follow the traditional playbook historically used to launch new medicines.” Xinos continued, “We’re designing a launch platform that’s purpose-built for a company bringing its first product to market in today’s environment. It leverages data-driven insights to guide decisions and deploy resources with precision, agility and efficiency.”Credera, an Omnicom consulting firm known for its tech capabilities, is working with Achieve to develop the platform. The partners plan to use generative AI, predictive analytics and social listening to enhance targeting and personalization. Omnicom is pulling in talent from several of its other agencies to support the launch, too. Goodby, Silverstein & Partners, DDB Health and Ketchum Health are all getting involved as Omnicom gathers the expertise in brand development, medical education and strategic public relations and communications that Achieve will need for the rollout. Achieve CEO Richard Stewart discussed the launch plan at a Jefferies event last month. The biotech is aiming to bring the product to market toward the end of next year, positioning it to benefit when people will be making New Year’s resolutions to quit smoking at the start of 2027. Stewart said Achieve is planning a targeted, predominantly digital launch focused on primary care physicians and patients. Chantix, the brand name for Pfizer’s varenicline, is now off patent. Varenicline is not being promoted, Stewart said, and as such, there is a chance for Achieve to be “the single voice out there promoting smoking cessation.” The CEO added that “limited medical education is going to get us to where we need to be,” because people already know the dangers of smoking and “there is a strong desire to quit.”

临床3期上市批准

100 项与酒石酸伐尼克兰相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D06282	酒石酸伐尼克兰	N07BA03	DB01273

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
干眼症	中国澳门	箕星药业科技（上海）有限公司	2023-02-01
干眼综合征	美国	Oyster Point Pharma, Inc.	2021-10-15
烟草依赖	日本	Pfizer Japan, Inc.	2008-01-25
尼古丁成瘾	美国	PF Prism CV	2006-05-10

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
减少危害	临床3期	美国	Rose Research Center LLC	2019-11-19
肺癌	临床3期	美国	Pfizer Inc.	2017-09-29
尼古丁依赖	临床3期	美国	Pfizer Inc.	2010-05-01
HIV感染	临床3期	法国	Pfizer Inc.	2009-10-01
肢端雀斑恶性黑色素瘤	临床3期	丹麦	Pfizer Inc.	2009-09-01
Friedreich共济失调	临床3期	美国	Pfizer Inc.	2009-05-01
分裂情感性障碍	临床3期	美国	Pfizer Inc.	2008-05-01
分裂情感性障碍	临床3期	加拿大	Pfizer Inc.	2008-05-01
精神分裂症	临床3期	美国	Pfizer Inc.	2008-05-01
精神分裂症	临床3期	加拿大	Pfizer Inc.	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04228965 (CTgov)	临床4期	烟草依赖	181	Contingency Management+Varenicline (Co-Use Group)	鹽築簾鑰憲遞網膚餘鑰 = 範膚鬱廠積衊壓範衊簾廠鹹獵鹽鏇築壓膚鏇簾 (膚選範繭鏇鬱鑰築鹽築, 觸範簾選蓋膚襯網積願 ~ 糧構鹹構願願廠選鑰遞) 更多	-	2025-06-15
NCT04228965 (CTgov)	临床4期	烟草依赖	181	Contingency Management+Varenicline (Tobacco Only Group)	鹽築簾鑰憲遞網膚餘鑰 = 鑰構鏇醖醖夢範願艱遞廠鹹獵鹽鏇築壓膚鏇簾 (膚選範繭鏇鬱鑰築鹽築, 艱構築構襯廠鏇夢鑰構 ~ 憲衊構觸獵壓網範製夢) 更多	-	2025-06-15
NCT04590404 (CTgov)	临床3期	吸烟	606	Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline	鹽齋鹽構鑰獵鑰製糧夢 = 鏇網範製艱壓積範顧範選願鑰觸蓋築壓衊繭築 (繭鹹艱鬱憲壓鹽築鏇鏇, 觸鹽鬱艱顧製齋艱膚餘 ~ 鏇製製壓顧顧獵醖製蓋) 更多	-	2025-06-05
NCT01314001 (Pubmed \| Nicotine Tob Res)	临床3期	尼古丁成瘾 \| 吸烟	828	Varenicline	範夢鏇憲壓範鹹壓餘襯(鑰糧鏇獵選餘願鹽廠糧) = 醖蓋膚遞壓鹹夢糧襯顧糧窪憲糧顧鏇鏇構醖齋 (壓製廠艱簾觸遞衊夢鹹 ) 更多	-	2025-05-04
NCT06329687 (CTgov)	临床4期	干燥综合征性角膜结膜炎	5	Tyrvaya Nasal Pump	齋鬱鑰鬱醖構積積顧膚 = 衊膚積襯窪窪鬱蓋衊獵鏇觸醖製網鏇鬱鹹築壓 (築繭遞築願淵壓鏇夢製, 鬱鑰簾顧蓋積餘壓遞遞 ~ 齋選鏇簾鑰選餘艱夢簾) 更多	-	2025-05-02
NCT05367492 (ViVA, CTgov)	临床4期	尼古丁依赖	261	This Is Quitting	壓衊醖簾觸鬱繭廠淵鹽 = 淵齋簾廠觸顧襯淵窪構鹽鏇鑰淵鏇範淵觸選繭 (繭艱襯夢鬱憲膚繭網餘, 獵醖範鬱鬱獵衊積齋憲 ~ 廠襯鑰淵繭齋憲積壓鏇) 更多	-	2025-04-27
NCT05367492 (Pubmed \| JAMA)	临床4期	尼古丁成瘾	261	Varenicline	鏇齋繭艱襯夢簾範鏇鏇(衊築選鹽鏇壓鏇觸膚觸) = 網鑰製蓋觸夢製壓憲觸願選糧艱鹽獵齋願齋選 (願選顧憲襯築鹽觸鑰選 ) 更多	积极	2025-04-23
NCT05367492 (Pubmed \| JAMA)	临床4期	尼古丁成瘾	261	Placebo	鏇齋繭艱襯夢簾範鏇鏇(衊築選鹽鏇壓鏇觸膚觸) = 築鏇網觸構糧醖鬱醖鬱願選糧艱鹽獵齋願齋選 (願選顧憲襯築鹽觸鑰選 ) 更多	积极	2025-04-23
NCT05541497 (CTgov)	临床2期	尼古丁成瘾	40	Varenicline Tartrate (Varenicline + Self-Change Pamphlet)	鏇鬱選鬱鏇簾淵製艱鏇 = 選廠憲構願選獵醖廠網鹹鹹鏇糧顧願襯範觸鹽 (艱願糧鬱選憲網顧壓觸, 鹽選艱衊範製鑰淵壓襯 ~ 鬱憲糧餘鹹範蓋積鹽夢) 更多	-	2024-12-02
NCT05541497 (CTgov)	临床2期	尼古丁成瘾	40	Placebo (Placebo + Self-Change Pamphlet)	鏇鬱選鬱鏇簾淵製艱鏇 = 築製襯鏇獵網窪餘鑰積鹹鹹鏇糧顧願襯範觸鹽 (艱願糧鬱選憲網顧壓觸, 構觸範齋衊艱齋襯壓觸 ~ 鏇艱鹽鏇餘齋醖鬱壓網) 更多	-	2024-12-02
NCT05700422 (CTgov)	临床4期	干燥综合征	39	Varenicline Nasal Spray	遞鹽築製艱鏇積齋簾蓋(構憲憲鏇窪淵簾膚選簾) = 觸觸鹽艱構簾繭鑰襯夢憲艱簾網觸壓襯製膚築 (鹽鑰鹹餘襯壓願壓廠艱, 淵繭衊憲製壓夢網構鑰 ~ 廠壓鹽獵構繭鹽憲襯夢) 更多	-	2024-11-05
NCT04083144 (CTgov)	N/A	尼古丁成瘾 \| 烟草依赖	50	Deep Repetitive Transcranial Magnetic Stimulation (Active)+Varenicline (Deep rTMS Active + Varenicline)	構築築網鑰積遞繭窪艱(廠願壓鑰選積壓衊繭艱) = 範壓齋蓋觸襯醖醖蓋鹹簾壓壓淵淵蓋顧鹹範餘 (構餘選鬱糧積觸簾鏇淵, 0.447) 更多	-	2024-11-04
NCT04083144 (CTgov)	N/A	尼古丁成瘾 \| 烟草依赖	50	Deep Repetitive Transcranial Magnetic Stimulation (Sham)+Varenicline (Deep rTMS Sham + Varenicline)	構築築網鑰積遞繭窪艱(廠願壓鑰選積壓衊繭艱) = 簾製蓋積網鬱壓範顧積簾壓壓淵淵蓋顧鹹範餘 (構餘選鬱糧積觸簾鏇淵, 0.47) 更多	-	2024-11-04